Proteris Biotech awarded second federal grant to develop a biologic eye drop for the treatment of epitheliopathy in dry eye

Proteris Biotech awarded second federal grant to develop a biologic eye drop for the treatment of epitheliopathy in dry eye

The National Eye Institute of the National Institutes of Health (NIH) has awarded Small Business Technology Transfer (STTR) grant R41-EY034396 to Proteris Biotech, Inc. (PB) to continue development of an innovative eye drop technology for the treatment of ocular surface damage in dry eye, also called epitheliopathy. The ultimate goal is a new U.S. Food and Drug Administration (FDA)-approved biologic drug. The grant begins September 30, 2023.